Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

Jürgen Behr, Michael Kreuter, Marius M Hoeper, Hubert Wirtz, Jens Klotsche, Dirk Koschel, Stefan Andreas, Martin Claussen, Christian Grohé, Henrike Wilkens, Winfried Randerath, Dirk Skowasch, F Joachim Meyer, Joachim Kirschner, Sven Gläser, Felix J F Herth, Tobias Welte, Rudolf Maria Huber, Claus Neurohr, Martin Schwaiblmair, Martin Kohlhäufl, Gert Höffken, Matthias Held, Andrea Koch, Thomas Bahmer, David Pittrow, Jürgen Behr, Michael Kreuter, Marius M Hoeper, Hubert Wirtz, Jens Klotsche, Dirk Koschel, Stefan Andreas, Martin Claussen, Christian Grohé, Henrike Wilkens, Winfried Randerath, Dirk Skowasch, F Joachim Meyer, Joachim Kirschner, Sven Gläser, Felix J F Herth, Tobias Welte, Rudolf Maria Huber, Claus Neurohr, Martin Schwaiblmair, Martin Kohlhäufl, Gert Höffken, Matthias Held, Andrea Koch, Thomas Bahmer, David Pittrow

Abstract

After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 2011, we investigated clinical management practices for patients with IPF according to physicians' diagnoses. A prospective, multicenter, noninterventional study with comprehensive quality measures including on-site source data verification was performed in Germany. 502 consecutive patients (171 newly diagnosed, 331 prevalent; mean±SD age 68.7±9.4 years, 77.9% males) with a mean disease duration of 2.3±3.5 years were enrolled. IPF diagnosis was based on clinical assessments and high-resolution computed tomography (HRCT) in 90.2%, and on surgical lung biopsy combined with histology in 34.1% (lavage in 61.8%). The median 6-min walk distance was 320 m (mean 268±200 m). The mean forced vital capacity was 72±20% pred and diffusing capacity of the lung for carbon monoxide was 35±15% pred. No drugs were administered in 17.9%, oral steroids in 23.7%, N-acetylcysteine in 33.7%, pirfenidone in 44.2% and other drugs in 4.6% of patients. Only 2.8% of the cohort was listed for lung transplantation. IPF patients were diagnosed in line with the new guidelines. They had more severe disease than those enrolled in recent randomised controlled trials. In addition to HRCT, the frequency of lung biopsies was surprisingly high. Treatment patterns varied substantially.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Copyright ©ERS 2015.

Figures

FIGURE 1
FIGURE 1
Comorbidities at baseline. CHD: coronary heart disease; DVT: deep venous thrombosis.
FIGURE 2
FIGURE 2
Symptoms indicative of idiopathic pulmonary fibrosis at baseline.
FIGURE 3
FIGURE 3
Procedures for idiopathic pulmonary fibrosis diagnosis (IPF). MDD: multidisciplinary discussion; HRCT: high-resolution computed tomography; BAL: bronchoalveolar lavage.
FIGURE 4
FIGURE 4
Previous and current drug treatment for idiopathic pulmonary fibrosis (IPF). VKA: vitamin-K antagonist.

References

    1. Raghu G, Collard HR, Egan JJ, et al. . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
    1. Travis WD, Costabel U, Hansell DM, et al. . An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
    1. Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013; 22: 281–291.
    1. Wilson JW, du Bois RM, King TE Jr. Challenges in pulmonary fibrosis: 8 – the need for an international registry for idiopathic pulmonary fibrosis. Thorax 2008; 63: 285–287.
    1. Blackwell TS, Tager AM, Borok Z, et al. . Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 2014; 189: 214–222.
    1. Ryerson CJ, Corte TJ, Collard HR, et al. . A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273–276.
    1. Alpert JS. Are data from clinical registries of any value? Eur Heart J 2000; 21: 1399–1401.
    1. Gitt AK, Bueno H, Danchin N, et al. . The role of cardiac registries in evidence-based medicine. Eur Heart J 2010; 31: 525–529.
    1. Behr J, Hoeper MM, Kreuter M, et al. . Charakteristika und Versorgung der idiopathischen Lungenfibrose. Rationale fur das INSIGHTS-IPF-Register. [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry.] Dtsch Med Wochenschr 2012; 137: 2586–2588.
    1. Behr J, Hoeper M, Kreuter M, et al. . Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res 2014; 1: e000010.
    1. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659–664.
    1. Quanjer PH, Tammeling GJ, Cotes JE, et al. . Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5–40.
    1. Quanjer PH, Stanojevic S, Cole TJ, et al. . Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.
    1. Quanjer PH, Stocks J, Cole TJ, et al. . Influence of secular trends and sample size on reference equations for lung function tests. Eur Respir J 2011; 37: 658–664.
    1. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2: 105–110.
    1. Kupferberg DH, Kaplan RM, Slymen DJ, et al. . Minimal clinically important difference for the UCSD shortness of breath questionnaire. J Cardiopulm Rehabil 2005; 25: 370–377.
    1. Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD 2012; 9: 12–15.
    1. Swigris JJ, Brown KK, Behr J, et al. . The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010; 104: 296–304.
    1. Ley B, Ryerson CJ, Vittinghoff E, et al. . A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684–691.
    1. Richeldi L, du Bois RM, Raghu G, et al. . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
    1. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
    1. Martinez FJ, de Andrade JA, Anstrom KJ, et al. . Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093–2101.
    1. Behr J, Günther A, Ammenwerth W, et al. . S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. [German guideline for diagnosis and management of idiopathic pulmonary fibrosis.] Pneumologie 2013; 67: 81–111.
    1. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646–664.
    1. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 2011; 37: 743–746.
    1. Ohshimo S, Bonella F, Cui A, et al. . Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043–1047.
    1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277–304.
    1. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012; 40: 519–521.
    1. Johnston ID, Prescott RJ, Chalmers JC, et al. . British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52: 38–44.
    1. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171–180.
    1. Collard HR, Tino G, Noble PW, et al. . Patient experiences with pulmonary fibrosis. Respir Med 2007; 101: 1350–1354.
    1. Peikert T, Daniels CE, Beebe TJ, et al. . Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1342–1348.
    1. Cottin V, Cadranel J, Crestani B, et al. . Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. Respir Med 2014; 108: 195–202.
    1. Wells AU, Behr J, Costabel U, et al. . Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J 2012; 39: 805–806.
    1. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589–595.
    1. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635–641.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever